Fig. 8 | Signal Transduction and Targeted Therapy

Fig. 8

From: Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression

Fig. 8

Hymecromone accelerate the recovery of COVID-19 patients from lymphocytopenia. Changes in lymphocytes (a), CRP (b), fibrinogen (c), and D-dimer (d) were calculated as the fold change of diverse clinical indicators per day in patients with lymphocytopenia. Data are presented by mean ± SEM. The significant difference was confirmed by the Mann–Whitney test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; ns, not significant

Back to article page